

## Acknowledgements

This symposium and the Clinical Research Group 249 are funded by the Deutsche Forschungsgemeinschaft (DFG). We thank Pfizer, Novartis and Miltenyi for their financial support of this symposium.

According to the German pharma industry code (FSA-Kodex) transparency regulations (§ 20, section 5) the member companies are committed to disclose the condition and scope of their financial support. For advertisement and exhibition: Pfizer 2500 €, Novartis 2000 € and Miltenyi 1000 €. The Carl Gustav Carus Management GmbH is responsible for the contractual and financial management of this event ([www.carus-management.de](http://www.carus-management.de)).

Please feel free to visit the industrial exhibition behind the reception.

